On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa
READ MORE 2021-02-25News List
BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM
VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri
READ MORE 2021-02-08
Progress in the development of new and efficient diabetes treatment drugs
Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy
READ MORE 2021-01-19
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
READ MORE 2020-12-22
Merck's new HIV drug Pedro (Doravirin) was approved in China
Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved
READ MORE 2020-12-08
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
READ MORE 2020-11-02
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
READ MORE 2020-10-18
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
READ MORE 2020-09-27
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
READ MORE 2020-09-09
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
READ MORE 2020-08-20